We’re developing targeted therapies to lower LDL cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, complementary, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more


Important Bempedoic Acid-Based Franchise Progress Updates

Last week was exciting for us at Esperion as we reported on tremendous progress achieved in enrolling patients for our… more

Posted by mlowe@esperion.com

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Evolution of Cholesterol Lowering Treatments

In Part I of our “History of LDL-cholesterol” blog series, I sat down with cardiovascular and lipids specialist, Dr. Antonio… more

Posted by mlowe@esperion.com

The Bempedoic Acid / Ezetimibe Combo Pill: Our Leading Complementary, Non-statin, Oral Therapy

This week we announced a major milestone: the U.S. Food and Drug Administration (FDA) confirmed the regulatory pathway to approval… more

Posted by mlowe@esperion.com